Adil S Virani

Learn More
Evidence • A 2008 systematic review1 compared benefits and harms of second-generation antidepressants. -No important difference in effectiveness. The few statistical differences found were not clinically important (eg, escitalopram 1.13 points better than citalopram on the 60-point MADRS scale [minimal clinically important difference ≥ 2]); sponsorship(More)
starting treatment of chronic indolent conditions at doses lower than those typically recommended in the product monographs. The approach we recommend is to use a very low dose when starting a new medication if the condition is not life-threatening or producing severe symptoms. Unfortunately, this approach is not used that much in practice. First, we should(More)
BACKGROUND The Medication Management Program was established at the Fraser Health Authority in 2005, in response to evidence suggesting that having pharmacists provide care to patients in their homes after discharge from hospital could reduce subsequent utilization of health service resources. OBJECTIVE To determine the effectiveness of the Medication(More)
BACKGROUND Several treatment options exist for type 2 diabetes, but little is known about the factors considered by health care providers (HCPs) and patients in Canada in making therapeutic decisions. This study explores perceptions and practices of HCPs and patients related to add-on (i.e., second-line) therapy for type 2 diabetes when initial therapy no(More)
  • 1